IL1A and myocarditis: There is an increasing number of reports and clinical trials exploring the efficacy of IL-1 blockade, essentially with the IL-1 receptor antagonist anakinra (blocking both the IL-1α and the IL-1β), for recurrent auto-inflammatory pericarditis, acute myocarditis with shock, and KD-related cardiac complications (13–15).